問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
莊其穆
下載
2020-05-01 - 2025-12-31
Condition/Disease
Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
Test Drug
Tiragolumab/TECENTRIQ (Atezolizumab)
Participate Sites5Sites
Recruiting5Sites
2019-02-01 - 2026-11-30
xxxxxx
Participate Sites8Sites
Recruiting8Sites
2019-02-01 - 2026-12-31
Advanced or Recurrent Endometrial Carcinoma
KEYTRUDA®/LENVIMA®
Participate Sites6Sites
Recruiting6Sites
2021-06-25 - 2024-01-04
Participate Sites3Sites
Recruiting3Sites
2018-07-30 - 2022-08-13
Not yet recruiting2Sites
Recruiting1Sites
Division of Obstetrics & Gynecology
2017-09-01 - 2023-04-20
Recruiting4Sites
Terminated1Sites
全部
